The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The prognostic impact of secondary-type mutations in patients with favorable risk AML
Dimitrios Kotsos, MD, Erasmus MC, Rotterdam, Netherlands, discusses the prognostic impact of secondary-type mutations in patients with acute myeloid leukemia (AML) who are considered favorable risk according to the European LeukemiaNe (ELN) 2022 risk classification guidelines. This study found that these patients had lower complete remission (CR) and overall survival (OS) rates than patients without secondary-type mutations. However, this was only true for patients aged over 60. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
